

Two novel racemic synthetic approaches to LTB₄ and LTB₃ methyl esters

Christine Gauthier, Dominique Castet, Yvan Ramondenc and Gérard Plé*

Université de Rouen, IRCOF, UMR 6014, F-76821 Mont Saint Aignan, France.
E-mail: Gerard.Ple@univ-rouen.fr; Fax: 33-2135522971; Tel: 33-2135522448

Received (in Cambridge, UK) 2nd October 2001, Accepted 21st November 2001
First published as an Advance Article on the web 18th December 2001

The formal racemic synthesis of LTB₄ and LTB₃ methyl esters **1** and **2** is reported by introducing in a one step-procedure the *E,E,Z*-conjugated trienic system provided by (1*E*,3*E*,5*Z*)-1,6-dibromohexa-1,3,5-triene **3** and (1*E*,3*E*,5*Z*)-1-bromo-7,7-diethoxyhepta-1,3,5-triene **4**, respectively, as building blocks.

Introduction

Leukotriene B₄ (LTB₄) (Fig. 1), an important metabolite of arachidonic acid,¹ biosynthesised *via* the 5-lipoxygenase pathway,² is one of the most potent inducers of chemotaxis, chemokinesis, aggregation and degranulation of leukocytes. Important roles in allergic,^{3*a*} inflammatory⁴ and immunological reaction⁵ have been attributed to LTB₄. On the other hand, following an analogous 5-lipoxygenase pathway, eicosa-5,8,11-trienoic acid is metabolised *in vivo* into LTB₃.⁶ The latter has also been reported to possess biological activities, similar to LTB₄.⁷





Fig. 1

As a result of their physiological importance and limited availability from biological sources, a number of synthetic routes to LTB₄⁸ and to LTB₃^{8*d*,8*h*,9} have been described in the literature.

Herein, we report two new synthetic approaches to LTB₄ and LTB₃ as their methyl esters **1** and **2** based on the great reactivity and versatility of our reagent (2*E*,4*E*)-5-bromopenta-2,4-dienal **5** (Scheme 1).¹⁰ Thus, as summarised in Scheme 1, it can be



Scheme 1

successfully used to yield diastereomerically pure (1*E*,3*E*,5*Z*)-1,6-dibromohexa-1,3,5-triene^{10*a*} **3** and (1*E*,3*E*,5*Z*)-1-bromo-

7,7-diethoxyhepta-1,3,5-triene¹¹ **4** (Scheme 1), following methodologies successfully developed in our group.^{10*a*,11}

One observes that, as in the target leukotrienes, the trienic *E,E,Z*-conjugated system already exists in compounds **3** and **4**; hence, they could be *a priori* seen as building blocks able to give access to the title methyl esters **1** and **2**.

To the best of our knowledge, the syntheses of LTB₄ and LTB₃ by a stereocontrolled introduction of the *E,E,Z* conjugated trienic unit, in a one step procedure, have not been reported so far.

Results and discussion


Two synthetic strategies were imagined, based mainly on the ability of the proposed starting materials **3**^{10*a*,12} and **4**¹¹ to afford lithio derivatives by stereocontrolled halogen–metal exchange reactions and subsequent treatment with an appropriate aldehyde.

Synthesis from (1*E*,3*E*,5*Z*)-1,6-dibromohexa-1,3,5-triene **3**


The 1*E*,3*E*,5*Z*-isomer of 1,6-dibromohexa-1,3,5-triene **3** has been previously prepared by us,^{10*a*} exploiting a Wittig reaction performed on (2*E*,4*E*)-5-bromopenta-2,4-dienal¹⁰ **5**.

Moreover, we have previously demonstrated that the two bromine atoms linked at C-1, C-6 significantly exhibit different reactivity when **3** is involved in a halogen–metal exchange reaction^{10*a*} or in a palladium-catalyzed cross-coupling process.¹³ This behaviour was considered of crucial importance since simple retrosynthetic disconnection revealed the availability of LTB₄ and LTB₃ from a 1*E*,3*E*,5*Z*-hexatriene dianion equivalent in reaction with two different aldehydes. Thus, the synthetic approaches to LTB₄ and LTB₃ methyl esters **1** and **2** were attempted as two successive selective bromine–lithium exchange reactions, followed by quenching of the reaction mixture with the required aldehyde (Scheme 2).

Indeed, a first bromine–lithium exchange reaction on pure 1*E*,3*E*,5*Z*-isomer **3**, by treatment with *tert*-butyllithium in diethyl ether at –75 °C, occurred with high selectivity on the bromine atom of the *E* double bond. The condensation with (3*Z*)-non-3-enal **6a** (synthetic approach to LTB₄ methyl esters **1**) or nonanal **6b** (synthetic approach to LTB₃ methyl esters **2**), afforded the desired monosubstituted compounds **7a** and **7b** in large excess over the side products **8a**, **9a** and **8b**, **9b**, respectively. After optimisation of the reaction conditions and column chromatography, the expected monobrominated derivatives **7a** and **7b** and the by-products **8a**, **9a** and **8b**, **9b** were isolated pure in the molar proportions **7a** : **8a** : **9a** 65 : 8 : 10 and **7b** : **8b** : **9b**



Scheme 2 Reagents and conditions: *i*, Bu^tLi, Et₂O, -75 °C, 90 min; (3*Z*)-non-3-enal **6a** or nonanal **6b**, 0 °C, 90 min.



Scheme 3 Reagents and conditions: *i*, Bu^tLi, Et₂O, -75 °C, 90 min; methyl 4-formylbutanoate **10**, 0 °C, 60 min.

56 : 10 : 10 (Scheme 2) and fully characterised. Discrimination between pure diastereomeric bromohydrins **7a** vs. **8a** and **7b** vs. **8b** and stereochemical analyses of all new compounds **7–9** were made by using ¹H NMR spectroscopy. The stereochemistry of the trienic system of compounds **7–9** has been determined from the *J* values of the different double bonds (for example, compound **7a**: *J*_{1,2} = 7.1; *J*_{3,4} = 13.5 and *J*_{5,6} = 13.8 Hz). All compounds **7–9** were obtained from the starting material **3** with total retention of configuration.

Finally, we note that (3*Z*)-non-3-enal **6a** was prepared in 91% yield by oxidation of the corresponding commercially available (3*Z*)-non-3-en-1-ol by using the Dess–Martin procedure.¹⁴

Keeping in mind that the bromohydrins **7a,b** are useful intermediates in the syntheses of LTB₄ and LTB₃ methyl esters **1** and **2**, respectively, the next step of the chemistry was straightforward. Thus, a second bromine–lithium exchange reaction was performed on pure isolated **7a,b** followed by quenching with methyl-4-formylbutanoate¹⁵ **10** (Scheme 3).

The LTB₄ methyl esters **1** (as a non-separable diastereomeric mixture) were obtained and isolated in analytical purity after column chromatography in 51% yield (with respect to **7a**, overall yield 33% vs. starting material **3**). We mention, however, the occurrence of the side acetylenic product **11**, in 25% yield (from **7a**), presumably as the result of the dehydrobromination of **7a** promoted by the Bu^tLi. This compound **11** has been isolated pure and fully analyzed.

Similar methodology carried out with **7b** afforded the LTB₃ methyl esters **2** (as a non-separable diastereomeric mixture) in 60% yield (overall yield 34% with respect to **3**).


The isolated pure LTB₄ and LTB₃ methyl esters **1** and **2** have been fully characterised using classical methods.

In our opinion, the above results reveal a simple and convenient route towards LTB₄ and LTB₃ precursors in a two-step

procedure from the readily available (1*E*,3*E*,5*Z*)-1,6-dibromohexa-1,3,5-triene **3**.

Synthesis via (1*E*,3*E*,5*Z*)-bromo-7,7-diethoxyhepta-1,3,5-triene **4**

In this second synthetic strategy, the starting material was (2*E*,4*E*)-5-bromopenta-2,4-dienal **5** (Schemes 1 and 4). As the chemistry depicted in Scheme 4 suggests, the crucial step should be the Wittig homologation of aldehyde **5** promoted by the diethyl acetal of **13**. Then, in order to prepare the diethoxy derivative **4**, the early stage of our research was inspired by the work of Bestmann¹⁶ concerning the diastereoselective synthesis of α,β-unsaturated aldehydes with high *Z* stereocontrol. However, in order to optimise the formation of **4**, we had to modify Bestmann's experimental protocol¹⁶ (Scheme 4).



Scheme 4 Reagents and conditions: *i*, EtBr, reflux, 2 days; *ii*, **5**, EtONa, THF, -10 °C, reflux, 12 h.

Surprisingly, we note that attempts at condensing directly the aldehyde **5** with the diethyl acetal of **13** (prepared from **12** and EtONa) failed since non-reproducible results were obtained. To ensure the accurate formation of **4**, we had to introduce the

non-enolisable aldehyde **5** to the reaction mixture containing the phosphonium salt **12** prior to EtONa. The addition of the latter generated *in situ* the diethyl acetal of **13**, which condensed with **5**, as soon as it had formed. Thus, the aldehyde **5** added to the phosphonium enol ether salt **12** (available from the Trippett and Walker¹⁷ phosphorylide reagent **13**), followed by sodium ethoxide (EtONa), afforded the new ω -bromo conjugated trienic diethyl acetal **4** in 70% yield (with respect to **5**). The total 1*E*,3*E*,5*Z* stereochemistry of the latter, seen as the key intermediate, was revealed by means of ¹H NMR spectroscopy.

Next, according to a bromine–lithium exchange reaction (treatment with Bu^tLi in Et₂O at –75 °C) performed on pure isolated compound **4** followed by quenching with (3*Z*)-non-3-enal **6a** or nonanal **6b**, the desired hydroxytrienic diethyl acetals **14a,b** were obtained in 76 and 78% yield (from **4**), after column chromatographic purification, with total retention of configuration (Scheme 5).

Hydrolysis of **14a,b** under mild acidic conditions yielded the corresponding crude aldehydes **15a,b** in (almost) quantitative yield (Scheme 5). The unstable compounds **15a,b** (isomerisation into the corresponding conjugated aldehydes with an all *E* configuration) have been used as crude product.

Finally, an ω -butanoate homologation was performed on the aldehyde **15b** by using trimethyl 4-lithioorthobutanoate,¹⁸ to afford the LTB₃ methyl esters **2** in 52% yield (from **15b**) after mild acidic hydrolysis (Scheme 6).

A similar procedure was previously reported by Taylor^{8k} for the synthesis of LTB₄ methyl esters **1** by condensation of the same reagent with a silylated trienic aldehyde analogous to our precursor **15a**.

Conclusions

In conclusion, we have succeeded in developing two new formal synthetic approaches to LTB₄ and LTB₃ methyl esters **1** and **2** by introduction of the conjugated trienic system in a one-step *E,E,Z*-stereocontrolled pathway.


From (1*E*,3*E*,5*Z*)-1,6-dibromohexa-1,3,5-triene **3** the LTB₄ and LTB₃ methyl esters **1** and **2** were obtained in two steps (in 33 and 34% overall yield respectively, *vs.* **3**) and from (2*E*,4*E*)-5-bromopenta-2,4-dienal **5** *via* the new reagent (1*E*,3*E*,5*Z*)-1-bromo-7,7-diethoxyhepta-1,3,5-triene **4**, the LTB₃ methyl esters **2** were obtained in four steps (overall yield 28% *vs.* **5**).

These new processes should be easily applicable to the synthesis of a wide variety of structural analogs. The synthesis with stereocontrol of the hydroxyallylic chiral centres is under investigation.

Experimental

General

IR spectra were recorded on a Perkin-Elmer 16 PC FT-IR spectrometer for samples as thin films. NMR spectra were recorded on a Bruker AC 200 MHz, Bruker Avance DPX 300 MHz, or




Scheme 6 Reagents and conditions: *i*, Li(CH₂)₃C(OMe)₃, Et₂O, 0 °C, 120 min.

Bruker AM 400 MHz with Aspect 3000 calculator. CDCl₃ or C₆D₆ was used as solvent. No SiMe₄ was added; rather, shifts were referenced to the solvent line (chemical shifts δ in ppm and coupling constants *J* in Hz). Mass spectra were performed on an ATI-Unicam Automass apparatus, fitted (or not) with a GC-mass coupling (high-resolution J&W column, 30 m, 0.25 mm ID, flow rate: 1.2 mL min⁻¹), or on a JEOL JMS AX-500 spectrometer. Analytical TLC was performed on Kieselgel 60F-254–0.25 mm plates and developed with UV (250 nm) or phosphomolybdic acid. Products were purified by silica gel column chromatography (SDS Company, 230–400 mesh). All reactions were carried out under dry Ar. Microanalyses were carried out in IRCOF Microanalysis Laboratory of Rouen. Melting points were measured on a Reichert-Jung microscope apparatus. Solvents were purified according to standard procedures.

(1*Z*,3*E*,5*E*,9*Z*)-1-Bromo-7-hydroxy-pentadeca-1,3,5,9-tetraene **7a**

To a solution of (1*E*,3*E*,5*Z*)-1,6-dibromohexa-1,3,5-triene^{10a,b} **3** (0.240 g, 1.00 mmol) in dry Et₂O (4 mL), cooled to –75 °C, under argon was added a solution of Bu^tLi (1.07 mL of a 1.7 M solution in pentane; 1.80 mmol) slowly with a syringe. The reaction mixture was stirred for 90 min and a solution of (3*Z*)-non-3-enal^{8j} **6a** (0.140 g, 1.00 mmol) in dry Et₂O (1 mL) was introduced. The reaction mixture was warmed to 0 °C and was stirred for 90 min before treatment with water (2 mL). After extraction with Et₂O (3 × 30 mL), the organic layer was dried (MgSO₄) and concentrated. By silica gel column chromatography [pentane–Et₂O (80 : 20 v/v)] we isolated and identified the expected monosubstituted compound **7a** (0.195 g, 65%) as a yellow oil, compound **8a** (0.025 g, 8%, yellow oil) and compound **9a** (0.035 g, 10%, yellow oil).

Compound 7a. $\nu_{\max}/\text{cm}^{-1}$ 3114, 3050, 2976, 1630, 1487, 1047 and 688; δ_{H} (300 MHz; C₆D₆) 0.86 (3H, t, *J* 6.7, 15-H₃), 1.15–



Scheme 5 Reagents and conditions: *i*, Bu^tLi, Et₂, –75 °C, 90 min; (3*Z*)-non-3-enal **6a** or nonanal **6b**, 0 °C, 2h; *ii*, PTSA, acetone, water, 0 °C, 45 min.

1.35 (6H, m, 12–14-H₂), 2.00 (2H, m, 11-H₂), 2.28 (2H, m, 8-H₂), 4.00 (1H, q, *J* 6.4 and 7.0, 7-H), 5.30–5.45 (2H, m, 9-H and 10-H), 5.60 (1H, dd, *J* 6.4 and 13.8, 6-H), 5.80 (1H, d, *J* 7.1, 1-H), 6.10 (2H, m, 4-H and 5-H), 6.25 (1H, dd, *J* 7.1 and 10.4, 2-H) and 6.60 (1H, dd, *J* 10.4 and 13.5, 3-H); δ_{C} (75 MHz; C₆D₆) 14.62 (C-15), 23.26 (C-14), 28.06 (C-11), 29.97 (C-12), 32.11 (C-13), 35.87 (C-8), 72.07 (C-7), 108.42 (C-1), 124.90 (C-9), 128.14 (C-3), 132.80 (C-4), 133.23 (C-2), 135.03 (C-10), 135.18 (C-5) and 139.07 (C-6) (Found: C, 60.38; H, 7.59. C₁₅H₂₃BrO requires C, 60.21; H, 7.75%).

(1E,3E,5Z,9Z)-1-Bromo-7-hydroxypentadeca-1,3,5,9-tetraene 8a. ν_{max} /cm⁻¹ 3134, 3060, 2985, 1630, 1055 and 670; δ_{H} (300 MHz; C₆D₆) 0.80 (3H, t, *J* 6.7, 15-H), 1.10–1.40 (6H, m, 12–14-H₂), 2.00 (2H, m, 11-H₂), 2.40 (2H, m, 8-H₂), 4.40 (1H, m, 7-H), 5.30–5.50 (4H, m, 5–6-H and 9–10-H), 5.62 (1H, m, 3-H), 5.78 (1H, d, *J* 13.6, 1-H), 6.30 (1H, dd, *J* 11.7 and 15.1, 4-H) and 6.52 (1H, dd, *J* 10.9 and 13.6, 2-H); δ_{C} (75 MHz; C₆D₆) 14.23 (C-15), 21.00 (C-14), 27.72 (C-11), 28.64 (C-12), 31.89 (C-13), 35.66 (C-8), 67.93 (C-7), 109.65 (C-1), 124.79 (C-9), 128.88 (C-5), 129.07 (C-4), 131.23 (C-2), 135.38 (C-10), 135.90 (C-3) and 137.72 (C-6) (Found: C, 60.38; H, 7.59. C₁₅H₂₃BrO requires C, 60.21; H, 7.75%).

(6Z,10E,12E,14Z,18Z)-9,16-Dihydroxytetraeicoso-6,10,12,14,18-pentane 9a. ν_{max} /cm⁻¹ 3346, 2920, 1654, 1466 and 1032; δ_{H} (300 MHz; C₆D₆) 0.88 (6H, m, 1-H₃ and 24-H₃), 1.15–1.34 (12H, m, 2–4-H₂, 21–23-H₂), 2.00 (4H, m, 5-H₂ and 20-H₂), 2.30 (4H, m, 8-H₂ and 17-H₂), 4.10 (1H, m, 9-H), 4.53 (1H, m, 16-H), 5.36–5.60 (5H, m, 6–7-H, 15-H and 18–19-H), 5.67 (1H, dd, *J* 5.9 and 15.0, 10-H), 6.02 (1H, t, *J* 11.5, 14-H), 6.14 (1H, dd, *J* 10.8 and 14.7, 12-H), 6.31 (1H, dd, *J* 10.8 and 15.0, 11-H) and 6.55 (1H, dd, *J* 11.5 and 14.7, 13-H); δ_{C} (75 MHz; C₆D₆) 14.46 (C-1 and C-24), 23.12, 29.86, 31.99 (C-2–4 and C-21–23), 27.94 (C-5 or C-20), 27.96 (C-20 or C-5), 36.07 (C-17 or C-8), 36.19 (C-8 or C-17), 68.15 (C-16), 72.20 (C-9), 125.25, 125.28, 133.25, 133.36, 134.73 (C-6–7, C-15 and C-18–19), 128.31 (C-13), 130.03 (C-14), 130.42 (C-11), 134.38 (C-12) and 137.70 (C-10); *m/z* (CI, CH₄) 389 (M⁺ + 29.1%), 361 (M⁺ + 1, 3), 343 (100), 325 (32), 249 (80), 231 (60), 189 (60), 137 (23) and 69 (28).

(1Z,3E,5E)-1-Bromo-7-hydroxypentadeca-1,3,5-triene 7b

According to the procedure described for preparation of compound **7a**, from (1E,3E,5Z)-1,6-dibromo-1,3,5-triene^{10a,b} **3** (0.240 g, 1.00 mmol) and using a solution of nonanal **6b** (0.140 g, 1.00 mmol) in dry Et₂O (1 mL) we isolated and identified, after silica gel column chromatography [pentane–Et₂O (80 : 20 v/v)], compound **7b** (0.170 g, 56%) as a yellow solid, compound **8b** (0.030 g, 10%, yellow oil) and compound **9b** (0.035 g, 10%, yellow oil).

Compound 7b. Mp 32–33 °C; ν_{max} /cm⁻¹ 3184, 3060, 2968, 1650, 1465, 1060 and 680; δ_{H} (300 MHz; C₆D₆) 0.90 (3H, t, *J* 6.8, 15-H₃), 1.20–1.40 (12H, m, 9–14-H₂), 1.42 (2H, m, 8-H₂), 3.86 (2H, m, 7-H₂), 5.63 (1H, dd, *J* 6.4 and 14.4, 6-H), 5.79 (1H, d, *J* 7.1, 1-H), 6.10 (2H, m, 4-H and 5-H), 6.26 (1H, dd, *J* 6.8 and 10.4, 2-H) and 6.61 (1H, dd, *J* 10.5 and 14.0, 3-H); δ_{C} (75 MHz; C₆D₆) 14.33 (C-15), 19.61, 23.05, 25.73, 29.98, 31.93 (C-9–14), 37.58 (C-8), 72.25 (C-7), 108.28 (C-1), 128.85 (C-3), 129.60 (C-4), 132.75 (C-2), 136.34 (C-5) and 139.88 (C-6) (Found: C, 59.64; H, 8.22. C₁₅H₂₅BrO requires C, 59.80; H, 8.36%).

(1E,3E,5Z)-1-Bromo-7-hydroxypentadeca-1,3,5-triene 8b. ν_{max} /cm⁻¹ 3204, 2922, 1686, 1640, 1466, 1090 and 990; δ_{H} (400 MHz; C₆D₆) 0.90 (3H, t, *J* 6.8, 15-H₃), 1.20–1.40 (12H, m, 9–14-H₂), 1.45 (2H, m, 8-H₂), 4.30 (2H, m, 7-H₂), 5.43 (1H, m, 6-H), 5.68 (1H, dd, *J* 11.5 and 15.4, 3-H), 5.91 (1H, d, *J* 13.5, 1-H), 6.32 (1H, dd, *J* 11.6 and 14.9, 4-H), 6.54 (1H, dd, *J* 11.2 and 13.5, 2-H) and 6.61 (1H, m, 5-H); δ_{C} (100 MHz; C₆D₆) 14.01 (C-15), 22.75, 25.47, 29.38, 29.69, 31.90 (C-9–14), 37.66 (C-8),

67.71 (C-7), 110.00 (C-1), 128.53 (C-5), 132.45 (C-4), 136.46 (C-6), 137.40 (C-2) and 139.57 (C-3); *m/z* (CI, CH₄) 331–329 (M⁺ + 29, 6%), 303–301 (M⁺ + 1, 1), 285–283 (9), 221 (10), 203 (18) and 174 (100) (Found: C, 59.57; H, 8.41. C₁₅H₂₅BrO requires C, 59.80; H, 8.36%).

(10E,12E,14Z)-9,16-Dihydroxytetraeicoso-10,12,14-triene

9b. ν_{max} /cm⁻¹ 3328, 2954, 1680, 1650, 1464, 1056 and 994; δ_{H} (300 MHz; C₆D₆) 0.80 (6H, m, 1-H₃ and 24-H₃), 1.00–1.20 (24H, m, 2–7-H₂ and 18–23-H₂), 1.25 (2H, m, 8-H₂), 1.40 (2H, m, 17-H₂), 4.05 (1H, m, 9-H), 4.55 (1H, m, 16-H), 5.45 (1H, t, *J* 9.8, 15-H), 5.65 (1H, dd, *J* 6.3 and 14.5, 10-H), 6.00 (1H, t, *J* 11.2, 14-H), 6.15 (1H, dd, *J* 10.8 and 14.0, 12-H), 6.25 (1H, dd, *J* 10.7 and 14.2, 11-H) and 6.55 (1H, dd, *J* 11.8 and 13.7, 13-H); δ_{C} (75 MHz; C₆D₆) 14.53 (C-1 and C-24), 22.95, 23.25, 26.03, 29.42, 30.62, 32.44 (C-2–7 and C-18–23), 30.24 (C-8), 30.96 (C-17), 68.25 (C-16), 72.64 (C-9), 128.50 (C-13), 129.81 (C-14), 130.23 (C-11), 134.36 (C-12), 135.55 (C-15) and 138.55 (C-10); *m/z* (EI) 364 (M⁺, 1%), 346 (M – H₂O₃), 328 (M – 2H₂O₃), 141 (74), 95 (34) and 57 (100); *m/z* (CI, CH₄) 347 (M⁺ + 1 – H₂O, 100%).

Methyl (6Z,8E,10E,14Z)-5,12-dihydroxyeicoso-6,8,10,14-tetraenoate 1: LTB₄ methyl esters

Under argon, a solution of Bu⁻Li (1.80 mL of a 1.79 M solution in pentane; 2.80 mmol) was added to a solution of compound **7a** (0.22 g, 1.00 mmol) in dry Et₂O (3 mL), cooled to –75 °C. The reaction mixture was stirred for 90 min and a solution of methyl 4-formylbutanoate¹⁵ **10** (0.10 g, 1.00 mmol) in dry Et₂O (2 mL) was introduced. The reaction mixture was warmed to 0 °C and stirred for 60 min before treatment with water (2 mL). After extraction with Et₂O (3 × 30 mL), the organic layer was dried (MgSO₄) and concentrated. By silica gel column chromatography [CH₂Cl₂–EtOAc (80 : 20 v/v)] we isolated and identified the LTB₄ methyl esters **1** (0.13 g, 51%) as a yellow oil, and the acetylenic derivative **11** (0.06 g, 25%, yellow oil).

Compound 1: LTB₄ methyl esters. ν_{max} /cm⁻¹ 3423, 2980, 1755, 1642, 1487, 1084 and 968; δ_{H} (300 MHz; CDCl₃) 0.87 (3H, t, *J* 6.6, 20-H₃), 1.21–1.37 (6H, m, 17–19-H₂), 1.50–1.75 (6H, m, 3-H₂, 4-H₂, and 2 × OH), 2.02 (2H, m, 16-H₂), 2.33 (4H, m, 2-H₂ and 13-H₂), 3.65 (3H, s, OCH₃), 4.20 (1H, m, 12-H), 4.55 (1H, m, 5-H), 5.35 (2H, m, 6-H and 14-H), 5.56 (1H, m, 15-H), 5.75 (1H, dd, *J* 6.0 and 14.7, 11-H), 6.06 (1H, t, *J* 11.3, 7-H), 6.15–6.35 (2H, m, 9-H and 10-H) and 6.47 (1H, dd, *J* 11.7 and 13.5, 8-H); δ_{C} (75 MHz; CDCl₃) 13.94 (C-20), 20.34 (C-3), 22.44 (C-19), 27.31 (C-16), 29.16 (C-17), 31.39 (C-18), 33.69 (C-2), 35.20 (C-13), 36.60 (C-4), 51.46 (OCH₃), 67.46 (C-5), 71.74 (C-12), 123.91 (C-14), 127.32 (C-8), 130.08 (C-7 and C-10), 133.51 (C-6), 133.84 (C-9), 133.94 (C-15), 136.69 (C-11) and 173.94 (C-1); *m/z* (EI) 333 (M⁺ – OH, 7%), 315 (10, M – H₂O – OH), 301 (9), 221 (12), 189 (14), 131 (25), 99 (68) and 61 (100) (Found: C, 71.74; H, 9.92. C₂₁H₃₄O₄ requires C, 71.96; H, 9.78%).

Methyl (8E,10E,14Z)-5,12-dihydroxyeicoso-8,10,14-trien-6-ynoate 11. ν_{max} /cm⁻¹ 3490, 3012, 2954, 2851, 1738, 1456, 1030 and 986; δ_{H} (300 MHz; CDCl₃) 0.82 (3H, t, *J* 6.5, 20-H₃), 1.20–1.40 (6H, m, 17–19-H₂), 1.70–1.80 (4H, m, 3-H₂ and 4-H₂), 2.00 (2H, m, 16-H₂), 2.20–2.36 (4H, m, 2-H₂ and 13-H₂), 3.62 (3H, s, OCH₃), 4.17 (1H, m, 12-H), 4.50 (1H, m, 5-H), 5.30 (1H, m, 15-H), 5.50–5.62 (2H, m, 8-H and 14-H), 5.78 (1H, dd, *J* 6.0 and 15.2, 11-H), 6.24 (1H, dd, *J* 10.8 and 15.2, 10-H) and 6.51 (1H, dd, *J* 10.8 and 15.5, 9-H); δ_{C} (75 MHz; CDCl₃) 14.02 (C-20), 20.53 (C-3), 22.51 (C-19), 27.37 (C-16), 29.22 (C-17), 31.45 (C-18), 33.52 (C-2), 35.19 (C-13), 36.97 (C-4), 51.58 (OCH₃), 62.41 (C-5), 71.52 (C-12), 84.05 (C-6), 92.28 (C-7), 110.60 (C-8), 123.81 (C-14 or C-15), 129.13 (C-10), 134.06 (C-15 or C-14), 138.29 (C-11), 141.39 (C-9), and 173.93 (C-1);

m/z (CI, CH₄) 377 (M⁺ + 29, 13%), 349 (M⁺ + 1, 8), 331 (100), 313 (38), 299 (84), 219 (50) and 177 (23) (Found: C, 72.54; H, 9.12. C₂₁H₃₂O₄ requires C, 72.38; H, 9.26%).

Methyl (6Z,8E,10E)-5,12-dihydroxyeicosa-6,8,10-trienoate 2: LTB₃ methyl esters

In the same manner as described for the preparation of the LTB₄ methyl esters **1**, from (1Z,3E,5E)-1-bromo-7-hydroxypentadeca-1,3,5-triene **7b** we isolated and identified, after silica gel column chromatography [CH₂Cl₂–EtOAc (80 : 20 v/v)], the LTB₃ methyl esters **2** (0.14 g, 60%) as a colourless oil. δ_{\max} –cm⁻¹ 3436, 2924, 1742, 1634, 1442, 1074 and 998; δ_{H} (400 MHz; CDCl₃) 0.82 (3H, t, *J* 6.3, 20-H₃), 1.15–1.70 (20H, m, 3-H₂, 4-H₂, 13–19-H and 2 × OH), 2.30 (2H, t, *J* 7.3, 2-H₂), 3.61 (3H, s, OCH₃), 4.10 (1H, q, *J* 6.5, 12-H), 4.53 (1H, m, 5-H), 5.36 (1H, t, *J* 10.3, 6-H), 5.70 (1H, dd, *J* 6.2 and 15.0, 11-H), 6.02 (1H, t, *J* 11.3, 7-H), 6.20 (2H, m, 9-H and 10-H) and 6.43 (1H, dd, *J* 10.9 and 15.0, 8-H); δ_{C} (100 MHz; CDCl₃) 14.02 (C-20), 20.74, 22.59, 25.34, 29.20, 29.48, 29.51, 30.26, 31.81 and 37.28 (C-3, C-4 and C-13–19), 33.77 (C-2), 51.44 (OCH₃), 67.45 (C-12), 72.21 (C-5), 127.29 (C-10 or C-9), 129.98 (C-8 and C-10 or C-9), 133.72 (C-7), 134.02 (C-6), 137.69 (C-11) and 173.94 (C-1); m/z (EI) 334 (M⁺ – H₂O, 2%), 303 (2), 219 (5), 161 (12), 129 (94) and 91 (100) (Found: C, 71.69; H, 10.08. C₂₁H₃₆O₄ requires C, 71.59; H, 10.23%).

(1E,3E,5Z)-1-Bromo-7,7-diethoxyhepta-1,3,5-triene 4

Under argon, a solution of (2E,4E)-5-bromopenta-2,4-dienal^{10a,b} **5** (0.15 g, 0.93 mmol) in dry THF (4 mL) was added to a solution of (2-ethoxyvinyl)triphenylphosphonium bromide¹⁶ **12** (0.96 g, 2.33 mmol) in dry THF (30 mL), at room temperature. To the solution cooled to –10 °C, were added EtONa (0.30 g, 4.41 mmol) and EtOH (0.25 mL). The reaction mixture was allowed to warm to room temperature and then was heated at reflux for 12 h, filtered on Celite, and concentrated. After silica gel column chromatography [light petroleum (distilled 50–65 °C)–Et₂O (70 : 30 v/v)] we isolated and identified compound **4** (0.17 g, 70%) as a yellow oil, ν_{\max} /cm⁻¹ 3062, 2974, 1608, 1562, 1322, 1118 and 992; δ_{H} (400 MHz; C₆D₆) 1.10 (6H, t, *J* 7.0, 2 × CH₃), 3.40 (2H, m, OCH₂CH₃), 3.57 (2H, m, OCH₂CH₃), 5.30 (1H, d, *J* 5.8, 7-H), 5.62 (1H, dd, *J* 11.5 and 14.8, 3-H), 5.66 (1H, dd, *J* 5.8 and 10.8, 6-H), 5.87 (1H, d, *J* 13.6, 1-H), 5.88 (1H, t, *J* 11.2, 5-H), 6.49 (1H, dd, *J* 11.4 and 13.8, 4-H) and 6.54 (1H, dd, *J* 12.0 and 13.6, 2-H); δ_{C} (100 MHz; C₆D₆) 15.54 (CH₃), 60.11 (OCH₂CH₃), 98.07 (C-7), 110.20 (C-1), 129.05 (C-4), 130.82 (C-6), 131.22 (C-2), 132.06 (C-5) and 137.64 (C-3); m/z (EI) 260–262 (M⁺, 7%), 215–217 (21), 181 (6), 159 (5), 136 (28), 107 (29) and 79 (100) (Found: C, 50.59; H, 6.56. C₁₁H₁₇BrO₂ requires C, 50.72; H, 6.65%).

(2Z,4E,6E,10Z)-1,1-Diethoxyhexadeca-2,4,6,10-tetraen-8-ol 14a

Under argon, a solution of Bu^tLi (0.6 mL of a 1.7 m solution in pentane; 1.02 mmol) was added to a solution of compound **4** (0.15 g, 0.58 mmol) in dry Et₂O (2 mL), cooled to –75 °C. The reaction mixture was stirred for 90 min and a solution of (3Z)-non-3-enal⁸ⁱ **6a** (0.20 g, 1.43 mmol) in dry Et₂O (2 mL) was introduced. The reaction mixture was stirred for 2 h and then warmed to 0 °C, before treatment with water (3 mL). After extraction with Et₂O (3 × 10 mL), the organic layer was dried (MgSO₄) and concentrated. By silica gel column chromatography [light petroleum (distilled 50–65 °C)–Et₂O 50 : 50 (v/v)] we have isolated and identified the compound **14a** (0.14 g, 76%) as a yellow oil. ν_{\max} /cm⁻¹ 3428, 2956, 1628, 1456, 1330, 1126 and 999; δ_{H} (400 MHz; C₆D₆) 0.85 (3H, t, *J* 7.1, 16-H₃), 1.10 (6H, t, *J* 7.0, 2 × OCH₂CH₃), 1.24 (7H, m, 13–15-H₂ and OH), 1.98 (2H, m, 12-H₂), 2.28 (2H, m, 9-H₂), 3.42 (2H, m, OCH₂CH₃),

3.60 (2H, m, OCH₂CH₃), 4.07 (1H, q, *J* 6.0, 8-H), 5.37 (1H, d, *J* 5.9, 1-H), 5.47 (2H, m, 10-H and 11-H), 5.59 (1H, dd, *J* 5.9 and 11.1, 2-H), 5.68 (1H, dd, *J* 6.0 and 15.1, 7-H), 6.08 (1H, dd, *J* 11.1 and 11.8, 3-H), 6.12 (1H, dd, *J* 10.9 and 14.8, 5-H), 6.28 (1H, dd, *J* 10.8 and 15.1, 6-H) and 6.73 (1H, dd, *J* 11.8 and 14.7, 4-H); δ_{C} (100 MHz; C₆D₆) 13.91 (C-16), 15.21 (OCH₂–CH₃), 22.58 (C-15), 27.41 (C-12), 29.32 (C-13), 31.47 (C-14), 35.53 (C-9), 59.85 (OCH₂CH₃), 71.31 (C-8), 97.93 (C-1), 124.87 (C-10), 127.86 (C-4), 128.88 (C-2), 129.73 (C-6), 131.64 (C-3), 132.62 (C-11), 134.78 (C-5) and 137.84 (C-7); m/z (EI) 322 (M⁺, 3%), 277 (100), 259 (7), 233 (9), 211 (68), 181 (90), 155 (21), 138 (74), 110 (92), 92 (81) and 51 (70) (Found: C, 74.63; H, 10.66. C₂₀H₃₄O₃ requires C, 74.49; H, 10.63%).

(2Z,4E,6E)-1,1-Diethoxyhexadeca-2,4,6-trien-8-ol 14b

According to the procedure described for the preparation of compound **14a**, from (1E,3E,5Z)-1-bromo-7,7-diethoxyhepta-1,3,5-triene **4** (0.38 g, 1.46 mmol) and a solution of nonanal **6b** (4.00 g) in dry Et₂O (1 mL) we isolated and identified, after silica gel column chromatography [pentane–Et₂O 80 : 20 (v/v)], compound **14b** (0.37 g, 78%) as a yellow oil, ν_{\max} /cm⁻¹ 3463, 2926, 1642, 1465, 1355, 1142 and 980; δ_{H} (400 MHz, C₆D₆) 0.90 (3H, t, *J* 6.9, 16-H₃), 1.12 (6H, t, *J* 7.1, 2 × OCH₂CH₃), 1.41 (14H, m, 9–15-H₂), 2.54 (1H, s, OH), 3.43 (2H, m, OCH₂CH₃), 3.57 (2H, m, OCH₂CH₃), 4.06 (1H, q, *J* 6.3, 8-H), 5.39 (1H, d, *J* 5.9, 1-H), 5.60 (1H, dd, *J* 5.9 and 11.1, 2-H), 5.70 (1H, dd, *J* 6.4 and 14.8, 7-H), 6.10 (1H, dd, *J* 11.0 and 11.9, 3-H), 6.13 (1H, dd, *J* 10.9 and 14.7, 5-H), 6.28 (1H, dd, *J* 10.7 and 14.9, 6-H) and 6.75 (1H, dd, *J* 11.8 and 14.5, 4-H); δ_{C} (100 MHz, C₆D₆) 14.32 (C-16), 15.54 (OCH₂CH₃), 23.03, 25.85, 29.70, 30.00, 30.06, 32.24, 37.76 (C-9–15), 60.11 (OCH₂CH₃), 72.33 (C-8), 98.22 (C-1), 128.09 (C-4), 129.18 (C-2), 129.88 (C-6), 132.00 (C-3), 135.19 (C-5) and 139.03 (C-7); m/z (EI) 324 (M⁺, 2%), 307 (10), 279 (46), 261 (10), 227 (11), 197 (6), 141 (10), 103 (100) and 85 (15) (Found: C, 74.18; H, 11.61. C₂₀H₃₆O₃ requires C, 74.03; H, 11.18%).

(2Z,4E,6E,10Z)-8-Hydroxyhexadeca-2,4,6,10-tetraenol 15a

At 0 °C, aq. toluene-*p*-sulfonic acid (0.25 g in 2 mL) was added to (2Z,4E,6E,10Z)-1,1-diethoxyhexadeca-2,4,6,10-tetraen-8-ol **14a** (0.19 g, 0.59 mmol) in acetone (10 mL). The mixture was stirred for 45 min, washed with saturated aq. NaHCO₃ (10 mL), and extracted with Et₂O (3 × 10 mL). Evaporation of the dried (MgSO₄) solution gave crude compound **15a** (0.14 g, 95%) as a yellow oil, ν_{\max} /cm⁻¹ 3423, 2945, 2820, 1672, 1451, 1124 and 990; δ_{H} (400 MHz; C₆D₆) 0.87 (3H, t, *J* 6.5, 16-H₃), 1.23–1.45 (7H, m, 13–15-H₂ and OH), 2.02 (2H, m, 12-H₂), 2.30 (2H, m, 9-H₂), 4.06 (1H, q, *J* 6.0, 8-H), 5.53 (2H, m, 10-H and 11-H), 5.69 (1H, dd, *J* 7.4 and 11.0, 2-H), 6.09 (1H, dd, *J* 11.0 and 14.5, 5-H), 6.07 (2H, m, 6-H and 7-H), 6.35 (1H, t, *J* 11.3, 3-H), 6.82 (1H, dd, *J* 11.3 and 14.4, 4-H) and 9.92 (1H, d, *J* 7.3, 1-H); δ_{C} (100 MHz; C₆D₆) 14.05 (C-16), 17.43 (C-15), 22.27 (C-12), 24.16 (C-13), 26.32 (C-14), 30.25 (C-9), 66.05 (C-8), 122.53 (C-10), 124.56 (C-2), 127.27 (C-7 or C-6), 128.06 (C-7 or C-6), 136.10 (C-11), 136.60 (C-5), 140.37 (C-3), 145.21 (C-4) and 186.93 (C-1).

(2Z,4E,6E)-8-Hydroxyhexadeca-2,4,6-trienol 15b

In the same manner as described for the preparation of **15a**, from (2Z,4E,6E)-1,1-diethoxyhexadeca-2,4,6-trien-8-ol **14b** (0.27 g, 0.84 mmol) we isolated and identified crude (2Z,4E,6E)-8-hydroxyhexadeca-2,4,6-trienol **15b** (0.21 g, 100%) as a yellow oil, ν_{\max} /cm⁻¹ 3408, 2924, 2854, 1668, 1462, 1134 and 1010; δ_{H} (200 MHz; C₆D₆) 0.90 (3H, t, *J* 6.2, 16-H₃), 1.26 (15H, m, 9–15-H₂ and OH), 3.92 (1H, m, 8-H), 5.61 (1H, dd, *J* 6.7 and 10.8, 2-H), 5.65 (1H, dd, *J* 11.2 and 13.8, 5-H), 6.07 (2H, m, 6-H and 7-H), 6.29 (1H, t, *J* 11.2, 3-H), 6.81 (1H, dd, *J* 11.2 and 14.2, 4-H) and 9.95 (1H, d, *J* 7.1, 1-H); δ_{C} (50 MHz; C₆D₆) 14.28

(C-16), 23.06, 25.73, 29.70, 30.01, 32.24, 37.64 (C-9–15), 71.94 (C-8), 126.03 (C-2), 127.06 (C-7 or C-6), 128.76 (C-6 or C-7), 141.64 (C-5), 142.95 (C-3), 145.77 (C-4) and 189.22 (C-1).

Methyl (6Z,8E,10E)-5,12-dihydroxyeicosa-6,8,10-trienoate 2: LTB₃ methyl esters

Under argon, a solution of Bu^tLi (4 mL of a 1.67 M solution in pentane; 6.68 mmol) was added to a solution of methyl 4-bromoorthobutanoate¹⁸ (0.84 g, 3.70 mmol) in dry Et₂O (10 mL), cooled to -75 °C. The reaction mixture was stirred for 90 min and a solution of compound **15b** (0.23 g, 0.93 mmol) in dry Et₂O (5 mL) was introduced. The reaction mixture was warmed to 0 °C and stirred for 2 h, before treatment with aq. CH₃COOH (5% w/v; 5 mL) and was then washed with water (5 mL). After extraction with Et₂O (3 × 20 mL), the organic layer was dried (MgSO₄) and concentrated. By silica gel column chromatography [pentane–Et₂O 30 : 70 (v/v)] we isolated and identified the LTB₃ methyl esters **2** (0.17 g, 52%) as a colourless oil. The analyses of LTB₃ methyl esters **2** were identical with those previously described in the case of the sample obtained from **7b** in the first manner.

References

- (a) P. Borgeat, M. Hamberg and B. Samuelson, *J. Biol. Chem.*, 1976, **251**, 7816; (b) P. Borgeat and B. Samuelson, *J. Biol. Chem.*, 1979, **254**, 7865; (c) P. Borgeat and B. Samuelson, *Proc. Natl. Acad. Sci. USA*, 1979, **76**, 3213; (d) O. Radmark, C. Malmsten, B. Samuelson, G. Goto, A. Marfat and E. J. Corey, *J. Biol. Chem.*, 1980, **255**, 11828; (e) E. J. Corey, J. O. Albright, A. E. Barton and S. I. Hashimoto, *J. Am. Chem. Soc.*, 1980, **102**, 1435; (f) P. J. Piper, *Physiol. Rev.*, 1984, **64**, 744; (g) B. Samuelson, S. E. Dahlen, J. A. Lindgren, C. A. Rouzer and C. N. Serhan, *Science*, 1987, **237**, 1171.
- (a) P. Borgeat and B. Samuelson, *J. Biol. Chem.*, 1979, **254**, 2643; (b) T. Shimizu, O. Radmark and B. Samuelson, *Proc. Natl. Acad. Sci. USA*, 1984, **81**, 89; (c) A. Wong, M. N. Cook, J. J. Foley, H. M. Saran, P. Marshall and S. M. Hwang, *Biochemistry*, 1991, **30**, 9346; (d) D. K. MacMillan, E. Hill, A. Sala, E. Sigal, T. Shuman, P. M. Henson and R. C. Murphy, *J. Biol. Chem.*, 1994, **269**, 26663.
- (a) A. W. Ford-Hutchinson, M. A. Bray, M. V. Doig, M. E. Shipley and M. J. Smith, *Nature*, 1980, **286**, 264; (b) P. Borgeat and P. Sirois, *J. Med. Chem.*, 1981, **24**, 121.
- (a) E. J. Goetzl, *New Engl. J. Med.*, 1980, **303**, 822; (b) P. M. Simmons and S. Monaco, *Biochem. Pharmacol.*, 1983, **32**, 1353.
- (a) M. Rola-Pleszczynski and P. Sirois, *Biochem. Biophys. Res. Commun.*, 1982, **102**, 1531; (b) D. G. Payan, A. Missirian-Bastian and E. J. Goetzl, *Proc. Natl. Acad. Sci. USA*, 1984, **81**, 1531.
- (a) S. Hammarström, *J. Biol. Chem.*, 1980, **255**, 7093; (b) S. Hammarström, *J. Biol. Chem.*, 1981, **256**, 2275; (c) S. Hammarström, *Biochim. Biophys. Acta*, 1981, **663**, 575; (d) L. Orning, K. Berström and S. Hammarström, *Eur. J. Biochem.*, 1981, **120**, 41.
- (a) B. A. Jackschik, A. R. Morrison and H. Sprecher, *J. Biol. Chem.*, 1983, **258**, 12797; (b) W. F. Stenson, S. M. Prescott and H. Sprecher, *J. Biol. Chem.*, 1984, **259**, 11784; (c) J. Evans, R. Zamboni, D. Nathaniel, C. Leveille and A. W. Ford-Hutchinson, *Prostaglandins*, 1985, **30**, 981.
- (a) E. J. Corey, A. Marfat, G. Goto and F. Brion, *J. Am. Chem. Soc.*, 1980, **102**, 7984; (b) Y. Guindon, R. Zamboni, C. K. Lau and J. Rokach, *Tetrahedron Lett.*, 1982, **23**, 739; (c) L. S. Mills and P. C. North, *Tetrahedron Lett.*, 1983, **24**, 409; (d) K. C. Nicolaou, R. E. Zipkin, R. E. Dolle and B. D. Harris, *J. Am. Chem. Soc.*, 1984, **106**, 3548; (e) Y. Le Merrer, C. Gravier, D. Micas-Languin and J. C. Depezay, *Tetrahedron Lett.*, 1986, **27**, 4161; (f) Y. Leblanc, B. J. Fitzsimmons, R. Zamboni and J. Rokach, *J. Org. Chem.*, 1988, **53**, 265; (g) Y. Le Merrer, C. Gravier-Pelletier, D. Languin-Micas, F. Mestre, A. Duréault and J. C. Depezay, *J. Org. Chem.*, 1989, **54**, 2409; (h) Y. Kobayashi, T. Shimazaki, H. Taguchi and F. Sato, *J. Org. Chem.*, 1990, **55**, 5324; (i) M. Avignon-Tropis, M. Treillhou, J. R. Pougny, I. Frécharde-Ortuno and G. Linstumelle, *Tetrahedron*, 1991, **47**, 7279; (j) D. Chemin and G. Linstumelle, *Tetrahedron*, 1992, **48**, 1943; (k) B. C. Borer and R. J. K. Taylor, *Synlett*, 1992, 117; (l) G. Solladié, A. Urbano and G. B. Stone, *Tetrahedron Lett.*, 1993, **34**, 6489; (m) A. Rodriguez, M. Nomen, B. W. Spur, J. J. Godfroid and T. H. Lee, *Tetrahedron*, 2001, **57**, 25 and references cited therein.
- (a) S. M. Roberts, B. J. Wakefield, J. A. Winders and H. G. Davies, *J. Chem. Soc., Chem. Commun.*, 1985, 1166; (b) B. Spur, A. Crea, W. Peters and W. König, *Arch. Pharm. (Weinheim, Ger.)*, 1985, **318**, 225; (c) D. Guillerme and G. Linstumelle, *Tetrahedron Lett.*, 1986, **27**, 5857; (d) I. C. Cotterill, G. Dorman, K. Faber, R. Jaouhari, S. M. Roberts, F. Scheinmann, J. Spreitz, A. G. Sutherland, J. A. Winders and B. J. Wakefield, *J. Chem. Soc., Chem. Commun.*, 1990, 1661; (e) F. Babudri, V. Fiandanese, O. Hassan, A. Punzi and F. Naso, *Tetrahedron*, 1998, **54**, 4327.
- (a) D. Soulez, G. Plé, L. Duhamel and P. Duhamel, *J. Chem. Soc., Chem. Commun.*, 1995, 563; (b) D. Soulez, G. Plé and L. Duhamel, *J. Chem. Soc., Perkin Trans. 1*, 1997, 1639; (c) N. Vicart, D. Castet-Caillabet, Y. Ramondenc, G. Plé and L. Duhamel, *Synlett*, 1998, 411; (d) D. Castet-Caillabet, Y. Ramondenc, G. Plé and L. Duhamel, *Tetrahedron*, 1999, **55**, 7583.
- D. Castet-Caillabet, PhD Thesis, University of Rouen, 2000.
- C. Gauthier, PhD Thesis, University of Rouen, 2000.
- P. Villiers, N. Vicart, Y. Ramondenc and G. Plé, *Eur. J. Org. Chem.*, 2001, 561.
- (a) D. B. Dess and J. C. Martin, *J. Am. Chem. Soc.*, 1991, **113**, 7277; (b) R. E. Ireland and L. Liu, *J. Org. Chem.*, 1993, **58**, 2899; (c) D. Hamprecht, K. Polborn and W. Steglich, *Angew. Chem., Int. Ed. Engl.*, 1995, **34**, 1314.
- M. Huckstep, R. J. K. Taylor and M. P. L. Caton, *Synthesis*, 1982, 881.
- H. J. Bestmann, K. Roth and M. Ettliger, *Chem. Ber.*, 1982, **115**, 161.
- S. Trippett and D. Walker, *J. Chem. Soc.*, 1961, 1266.
- (a) B. C. Borer and R. J. K. Taylor, *Synlett*, 1990, 601; (b) G. Casy, J. W. Patterson and R. J. K. Taylor, *Org. Synth.*, 1988, **67**, 193.